Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 10
Submit an article Journal homepage
261
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Long-term molecular remission in Philadelphia-positive acute lymphoblastic leukemia elderly patient after dasatinib discontinuation

Ernesto VignaHematology Unit, Department of Onco-Hematology, AO Of Cosenza, Cosenza, Italy;
,
Massimo GentileHematology Unit, Department of Onco-Hematology, AO Of Cosenza, Cosenza, Italy;
,
Giovanna GiagnuoloHematology Unit, Department of Onco-Hematology, AO Of Cosenza, Cosenza, Italy;
,
Anna Grazia RecchiaHematology Unit, Department of Onco-Hematology, AO Of Cosenza, Cosenza, Italy; ;Biotechnology Research Unit, Aprigliano, AO/ASP Of Cosenza, Cosenza, Italy;
,
Sabrina BossioHematology Unit, Department of Onco-Hematology, AO Of Cosenza, Cosenza, Italy; ;Biotechnology Research Unit, Aprigliano, AO/ASP Of Cosenza, Cosenza, Italy;
,
Laura De StefanoHematology Unit, Department of Onco-Hematology, AO Of Cosenza, Cosenza, Italy; ;Biotechnology Research Unit, Aprigliano, AO/ASP Of Cosenza, Cosenza, Italy;
,
Rosellina MorelliNuclear Medicine Unit, Department of Onco-Hematology, AO Of Cosenza, Cosenza, Italy
&
Fortunato MorabitoHematology Unit, Department of Onco-Hematology, AO Of Cosenza, Cosenza, Italy; ;Biotechnology Research Unit, Aprigliano, AO/ASP Of Cosenza, Cosenza, Italy; Correspondence[email protected]
 show all
Pages 2445-2447 | Received 03 Oct 2015, Accepted 03 Jan 2016, Published online: 15 Feb 2016

References

  • Gökbuget N. How I treat older patients with ALL. Blood. 2013;122:1366–1375.
  • Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–3678.
  • Mahon FX, Réa D, Guilhot J, et al. Discontinuation of Imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
  • Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of Imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study. Blood. 2013;122:515–522.
  • Riva G, Luppi M, Lagreca I, et al. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following Imatinib withdrawal in an elderly patient with Philadelphia-positive ALL. Br J Haematol. 2014;164:299–302.
  • Rea D, Raffoux E, Cayuela JM, et al. Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with Imatinib-resistant myeloblastic-phase chronic myeloid leukaemia. Leukemia. 2009;23:1158–1159.
  • Benjamini O, Dumlao TL, Kantarjian H, et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014;89:282–287.
  • Riva G, Luppi M, Barozzi P, et al. Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph + acute lymphoblastic leukemia during long-term Imatinib mesylate treatment. Blood. 2010;115:1512–1518.
  • Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135–139.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.